JP6775426B2 - 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途 - Google Patents

臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途 Download PDF

Info

Publication number
JP6775426B2
JP6775426B2 JP2016572917A JP2016572917A JP6775426B2 JP 6775426 B2 JP6775426 B2 JP 6775426B2 JP 2016572917 A JP2016572917 A JP 2016572917A JP 2016572917 A JP2016572917 A JP 2016572917A JP 6775426 B2 JP6775426 B2 JP 6775426B2
Authority
JP
Japan
Prior art keywords
cells
ucb
hla
population
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508479A (ja
JP2017508479A5 (enExample
Inventor
パトリック ヘンノ、
パトリック ヘンノ、
ゴンザレス、 マーティン ビラルバ
ゴンザレス、 マーティン ビラルバ
ヤン ル チャオ
ヤン ル チャオ
ロッシ ジャン‐フランソワ
ロッシ ジャン‐フランソワ
Original Assignee
エメルセル エスエーエス
エメルセル エスエーエス
インスティチュート ナショナル ド ラ サンテ エト ド ラ レチェルシー メディカレ （インサーム）
インスティチュート ナショナル ド ラ サンテ エト ド ラ レチェルシー メディカレ （インサーム）
サントル オピタリエ ユニヴェルシテール ド モンペリエ
サントル オピタリエ ユニヴェルシテール ド モンペリエ
ユニヴェルシテ ド モンペリエ
ユニヴェルシテ ド モンペリエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エメルセル エスエーエス, エメルセル エスエーエス, インスティチュート ナショナル ド ラ サンテ エト ド ラ レチェルシー メディカレ （インサーム）, インスティチュート ナショナル ド ラ サンテ エト ド ラ レチェルシー メディカレ （インサーム）, サントル オピタリエ ユニヴェルシテール ド モンペリエ, サントル オピタリエ ユニヴェルシテール ド モンペリエ, ユニヴェルシテ ド モンペリエ, ユニヴェルシテ ド モンペリエ filed Critical エメルセル エスエーエス
Publication of JP2017508479A publication Critical patent/JP2017508479A/ja
Publication of JP2017508479A5 publication Critical patent/JP2017508479A5/ja
Application granted granted Critical
Publication of JP6775426B2 publication Critical patent/JP6775426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
JP2016572917A 2014-03-07 2015-03-09 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途 Active JP6775426B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305332.0 2014-03-07
EP14305332 2014-03-07
PCT/EP2015/054837 WO2015132415A1 (en) 2014-03-07 2015-03-09 Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020071370A Division JP2020114248A (ja) 2014-03-07 2020-04-10 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途

Publications (3)

Publication Number Publication Date
JP2017508479A JP2017508479A (ja) 2017-03-30
JP2017508479A5 JP2017508479A5 (enExample) 2018-04-19
JP6775426B2 true JP6775426B2 (ja) 2020-10-28

Family

ID=50277168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016572917A Active JP6775426B2 (ja) 2014-03-07 2015-03-09 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途
JP2020071370A Pending JP2020114248A (ja) 2014-03-07 2020-04-10 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020071370A Pending JP2020114248A (ja) 2014-03-07 2020-04-10 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途

Country Status (8)

Country Link
US (1) US20170073637A1 (enExample)
EP (1) EP3114215B1 (enExample)
JP (2) JP6775426B2 (enExample)
CN (1) CN106164256B (enExample)
CA (1) CA2941519C (enExample)
DK (1) DK3114215T3 (enExample)
ES (1) ES2880718T3 (enExample)
WO (1) WO2015132415A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
KR20180086204A (ko) * 2015-11-05 2018-07-30 글리코스템 떼라퓨틱스 비.브이. 면역치료법에 사용하기 위한 조성물
EP3411414A4 (en) * 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
DK3755347T3 (da) * 2018-02-21 2025-08-04 Univ Texas Universelle antigenpræsenterende celler og anvendelser deraf
KR20210052494A (ko) 2018-08-27 2021-05-10 아피메트 게엠베하 항체 구조물이 사전 로드된 동결 보존된 nk 세포
WO2020152661A1 (ja) * 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
JP2021035400A (ja) * 2020-12-07 2021-03-04 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
CA2703428A1 (en) * 2010-05-11 2011-11-11 Mcgill University Health Center Pooled cord blood units
WO2012009422A1 (en) * 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
KR101447546B1 (ko) * 2011-03-03 2014-10-08 한국생명공학연구원 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
JP5840876B2 (ja) * 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
WO2014123879A1 (en) * 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta

Also Published As

Publication number Publication date
ES2880718T3 (es) 2021-11-25
CA2941519C (en) 2022-09-06
DK3114215T3 (da) 2021-06-21
JP2017508479A (ja) 2017-03-30
US20170073637A1 (en) 2017-03-16
WO2015132415A1 (en) 2015-09-11
CN106164256A (zh) 2016-11-23
EP3114215A1 (en) 2017-01-11
JP2020114248A (ja) 2020-07-30
CN106164256B (zh) 2021-08-10
CA2941519A1 (en) 2015-09-11
EP3114215B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
JP6775426B2 (ja) 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途
JP7072808B2 (ja) 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
US20240050478A1 (en) Method for Culturing Natural Killer Cells Using T Cells
US9404083B2 (en) Method for amplifying NK cells
CN104321425B (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
EP3000876B1 (en) Method for preparing nk cells
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
Hosseini et al. Ex vivo expansion of CD3depleted cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy
WO2016010153A1 (ja) 免疫細胞療法用ｔ細胞の誘導方法
US12091684B2 (en) Platelet-derived mitochondria treatment and method of generating multipotent cells
KR20120054018A (ko) 일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
HK1171949A (en) Pharmaceutical composition containing transiently surviving ctl
HK1190432B (en) Method for amplifying nk cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181023

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201006

R150 Certificate of patent or registration of utility model

Ref document number: 6775426

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250